LMU spin-off Eisbach Bio GmbH has received a Texas Therapeutics Company Award from the Cancer Prevention and Research Institute of Texas (CPRIT). This grant will support the clinical development of EIS-12656, which targets challenging cancers with homologous recombination defects (HRD). Eisbach Bio GmbH had previously secured $4.5 million in funding in June 2024. Juni 2024 4,5 Mio $ Fördermittel gesichert.
Victor Ambros and Gary Ruvkun have been awarded the 2024 Nobel Prize for their discovery of the first microRNA, lin-4, in C. elegans.
This is the second consecutive Nobel Prize for nucleic acids, following the 2023 Nobel Prize for Katalin Karikó and Drew Weissmann for their work on
mRNA technology. The development of nucleic acid-based therapeutics is the goal of the Cluster for Nucleic Acid Therapeutics Munich (CNATM).
In CNATM leading academic groups and 14 biotech companies are working together to achieve this goal. Several CNATM partners are focusing on microRNA-based therapeutics (rnatics GmbH, Secarna Pharmaceuticals GmbH, Engelhardt Group at the Institut for Pharmacology and Toxikology at TUM, Yildirim Group at the Helmholtz München).
Prof. Irmela Jeremias is a pediatrician at the Hauner Children’s Hospital of LMU and a scientist at Helmholtz München. For her research on new targets to fight leukemia, she received a Reinhart Koselleck grant from the German Research Foundation (DFG). This grant supports highly innovative and promising projects. Her project aims to “Identify new targeted cancer therapies using in vivo CRISPR/Cas9 dropout screens in PDX models”.
The European Research Council has awarded the LMU chemist a grant for the preclinical development of a new drug for treating leukemia in high-risk patients.
Continue reading
The formation of the biotech spinoff RNhale can be traced back to Professor Olivia Merkel’s groundbreaking research
Continue reading
EpiCure, eine Firmenidee, die auf Ausgründung wartet, gehört mir ihrem Konzept zu den 5 Siegern…
Continue readingEisbach Bio GmbH (“Eisbach” or the “Company”), a privately-held clinical-stage biotechnology company pioneering cancer medicines leveraging synthetic lethality,
Continue readingYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Google Maps. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information